Dna X (SONM) Cash & Equivalents (2018 - 2026)

Dna X has reported Cash & Equivalents for 9 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 43.5% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 43.5% YoY), and the FY2025 full-year result was $1.3 million, down 75.61% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.2 million, down from $1.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $15.5 million in Q3 2022, with the low at $101000.0 in Q1 2024.
• Historically, Cash & Equivalents has averaged $4.3 million across 5 years, with a median of $2.0 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 98.95% — and 2025, when it soared 1994.06%.
• Dna X's Cash & Equivalents stood at $1.5 million in 2022, then surged by 526.05% to $9.4 million in 2023, then tumbled by 43.14% to $5.3 million in 2024, then slumped by 75.61% to $1.3 million in 2025, then decreased by 8.29% to $1.2 million in 2026.
• The last three Cash & Equivalents figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.